key: cord-0968064-kmfp7km8 authors: Jean-Mignard, Estelle; Luna, Gonzalo De; Pascal, Laurent; Agouti, Imane; Thuret, Isabelle title: SARS-CoV-2 infection in patients with β-thalassemia: the French experience date: 2021-07-01 journal: Transfus Clin Biol DOI: 10.1016/j.tracli.2021.06.007 sha: 277e5aa4af7413227b7cc9e7102864f5f4cc04b0 doc_id: 968064 cord_uid: kmfp7km8 Introduction: Because of iron overload complications, thrombosis and infectious predisposition, patients with severe forms of thalassemia are likely to be at increased risk of COVID-19 complications. Results: A national survey conducted during the year 2020 across the French reference centers for hemoglobinopathies identified 16 cases of COVID-19 confirmed by RT-PCR in beta-thalassemia patients. Their age ranged from 11 months to 60 years. 15 patients were transfusion dependent and 6 were splenectomized. Concerning iron-overload related complications, none had diabetes or cirrhosis and only one had experienced heart failure. All 4 pediatric patients were pauci-symptomatic during the viral episode. Three patients (41, 49 and 57 years old) developed COVID-19 pneumonia requiring oxygen-therapy without the need for mechanical ventilation. Neutropenia (absolute neutrophils count <0.5 10 9/L) was observed in 2 patients receiving long-term treatment with hydroxycarbamide and deferiprone. No thrombosis event, organ failure or death occurred. All patients recovered. Conclusion: Severity of COVID-19 in this population of early-aged patients appeared increased compared to the general population but remained mild to moderate as already reported in the few series reported in the literature. Occurrence of adverse events related to chronic treatment administered in thalassemia disease may be favored by the infectious episode. . During the year 2020, a total of 2,600,498 confirmed cases of COVID-19 and more than 64,000 deaths were recorded in France [2] . Although the majority of infected patients experienced moderate or asymptomatic disease, advanced age and the presence of comorbidities increase the risk for developing serious complications during COVID-19 for which there is currently no curative treatment [3] . Thalassemia is a hereditary disorder characterized by a decrease in the production of normal hemoglobin. In the most severe forms of beta-thalassemia (beta-thalassemia major or Transfusion-Dependent Thalassemia, TDT) the absent or decreased synthesis of betaglobin chains leads to profound anemia requiring long-term transfusion therapy since early infancy. The main consequence of transfusions being iron overload. Long-term iron chelation therapy is always associated to regular transfusion regimen [4, 5] . In intermediate severity forms, rarer than TDT, anemia is less severe and transfusions are not indicated or only occasionally (non-transfuso-dependent beta-thalassemia, NTDT) but patients are exposed to the complications stemming from chronic hemolytic anemia, ineffective erythropoiesis, iron overload secondary to intestinal iron hyperabsorption and predisposition to thromboembolic events [5] [6] . As pointed out by the International Thalassemia Federation (TIF) [7] , patients with severe forms of thalassemia should be considered as vulnerable to COVID-19. Several immunosuppression mainly related to splenectomy which is often performed to reduce transfusion volumes, iron overload related organ damage such as heart or liver disease and diabetes as well as the risk of decompensation of unrecognized or partial endocrine insufficiency, in particular adrenal insufficiency [4, 5, [8] [9] [10] . In addition, both COVID-19 and thalassemia (due to the circulation of thalassemia pro-coagulant red blood cells and splenectomy often performed in thalassemia patients) increased risk of thromboembolism events [11] [12] [13] [14] . In the United Kingdom, the NHSE (National-Health Service England) also identified in patients with hemoglobinopathies some specific risks during COVID-19. They resulted from a possible increase in the frequency and or severity of adverse effects (particularly renal or hematological side effects) related to long-term treatments prescribed in thalassemia patients mainly chelation therapy agents [15] . In order to better describe the frequency and manifestations of COVID-19 in thalassemia patients living in France, we report the cases of SARS-CoV-2 infection that occurred during the year 2020. Beta-thalassemia is widespread in the world but is a rare disease in France with an estimated prevalence of 12 per 1,000,000 for severe forms. According to Thalassemia National Registry, the current number of patients with beta- France is estimated at around 600 patients. This number exclude "ex-thalassemia" patients who have been successfully treated with hematopoietic cell transplantation [16] . All practitioners involved in the management of patients with hemoglobinopathies Table 1 . Additional clinical information could not be obtained for a 16 th patient reported. We report 16 cases of SARS-CoV-2 infection that occurred in beta-thalassemia patients living in France during the 2 epidemic waves of the year 2020. All except one were TDT while the French cohort included around 600 patients (2/3 of TDT and 1/3 of NTDT) [16] . This over-representation is probably partly the consequence of a selection bias, TDT patients being more tested even for minimal symptoms due to their frequent visits to day hospitals for blood transfusion. J o u r n a l P r e -p r o o f 8 and 2 subjects with cardiac iron overload. We also note that the 3 patients who developed pneumonia fell into each of the 3 risk categories, illustrating the need for large international studies to validate the classification proposed by the TIF. All patients were over 40 years old, a relatively advanced age for patients suffering from TDT, whose current life expectancy is estimated to be around 50 years [22] . Two subjects were overweight and none had hypertension. All three progressed favorably with pulmonary evaluation, at 2-3 months post infection, in favor of the absence of respiratory sequelae. There are key challenges related to the prompt management of chronic treatments, especially chelation therapy, during COVID-19 in thalassemia patients. While chelation therapy is most often continued during infection, its suspension should be discussed in patients with severe disease. The renal toxicity of deferasirox may be favored by COVID-19 gastro-intestinal symptoms or the administration of NSAIDs [23] . This chelation agent should be suspended in case of renal insufficiency. Treatment with deferipone can be complicated by drug-induced agranulocytosis: neutropenia should always be sought in the event of fever or infection and, if present, lead to immediate discontinuation of treatment [24] . The occurrence of agranulocytosis in 2 patients treated with both deferiprone and hydroxycarbamide illustrates the need for closely monitoring the blood count during COVID-19 in thalassemia patients receiving deferiprone and/or hydroxycarbamide which is also a potentially myelotoxic drug in thalassemia patients. Of note, except for 2 patients, no increase in blood requirement was observed. Inversely, the introduction of continuous parenteral chelation with deferoxamine could be discussed in cases of acute cardiac decompensation [24] . Overall, the long-term thalassemia treatment must be systematically evaluated and sometimes adapted. Finally, despite the lack of specific data available among thalassemia patient population, 3 additional risks of severe infection should also be systematically evaluated and/or prevented: 1-the risk of latent or existing iron-overload adrenal insufficiency decompensation, 2-the increased thromboembolic risk with the recommendation of prophylactic anticoagulation for patients with severe COVID-19 and 3the risk of secondary bacterial infection particularly in splenectomized patients. Page 9 of 13 J o u r n a l P r e -p r o o f 9 In our cohort, as in the literature, COVID-19 in thalassemia patients was associated with a high rate of hospitalization and complications for an early age population. The majority of cases reported in France had a favorable outcome probably due to the rarity of the most severe hemochromatosis complications such as diabetes, heart failure or cirrhosis and a level of iron overload assessed by MRI most often moderate. When managing COVID-19, specific risks related to both thalassemia related co-morbidities and long-term treatments should be taken into account. The authors declare no competing financial interests. World Health Organization. Coronavirus disease (COVID-19) pandemic COVID-19 : Point épidémiologique du 31 décembre 2020 Risk factors for Covid-19 severity and fatality: a structured literature review Beta-thalassemia Identification and key management of non-transfusion-dependent thalassaemia patients: not a rare but potentially underrecognised condition COVID-19 and thalassaemia: A position statement of the Thalassaemia International Federation Survival and complications in thalassemia The ICET-A Survey on Current Criteria Used by Clinicians for the Assessment of Central Adrenal Insufficiency in Thalassemia: Analysis of Results and Recommendations Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management Hypercoagulability in nontransfusion-dependent thalassemia Redefining thalassemia as a hypercoagulable state Splenectomy and thrombosis: the case of thalassemia intermedia Pharmacologic thromboprophylaxis and thrombosis in hospitalized patients with COVID-19: a pooled analysis Real-time national survey of COVID-19 in hemoglobinopathy and rare inherited anemia patients Registre des patients thalassémiques en France / Portail Epidémiologie -France Health Databases (aviesan.fr) Preliminary Data on COVID-19 in Patients with Hemoglobinopathies: A Multicentre ICET-A Study SARS-CoV-2 infection in beta thalassemia: Preliminary data from the Italian experience Clinical characteristics of children and young people admitted to hospital with COVID-19 in United Kingdom: prospective multicentre observational cohort study Screening and severity of coronavirus disease 2019 (COVID-19) in children in Prevalence and severity of Coronavirus disease 2019 (COVID-19) in Transfusion Dependent and Non-Transfusion Dependent β-thalassemia patients and effects of associated comorbidities: an Iranian nationwide study Management of the aging betathalassemia transfusion-dependent population -The Italian experience Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload Deferiprone-induced agranulocytosis: 20 years of clinical observations Treatment of heart failure in adults with thalassemia major: response in patients randomised to deferoxamine with or without deferiprone